A Phase 1 Study of LY3127804 as Monotherapy and in Combination With Ramucirumab in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2017
At a glance
- Drugs LY 3127804 (Primary) ; Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 04 Dec 2017 Status changed from active, no longer recruiting to completed.
- 03 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2017 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018.